Explanation of the “Recommendation on antiviral therapy to hepatitis B/C virus related hepatocellular carcinoma”
-
摘要:
<正>肝细胞癌(HCC)既是慢性嗜肝病毒感染的延续,又有肝功能代偿/失代偿状态,更是实体肿瘤形成的特殊状态,需要多学科共同参与。《HBV/HCV相关性肝细胞癌抗病毒治疗专家建议》(下文简称《建议》)强调的是抗病毒治疗的必要性,是在手术或射频治疗(RFA)等根治性手术或经皮肝动脉插管化疗栓塞术(TACE)、适应性放射性治疗、全身化疗等姑息性治疗方案的基础应用上,是综合治疗的一部分。
-
Key words:
- hepatitis B /
- hepatitis C /
- liver neoplasms /
- therapy /
- guidebooks
-
[1]Bouchard MJ, Navas-Martin S.Hepatitis B and C virus hepa-tocarcinogenesis:lessons learned and future challenges[J].Cancer Lett, 2011, 305 (2) :123-143. [2]Bartosch B, Thimme R, Blum HE, et al.Hepatitis C virus-induced hepatocarcinogenesis[J].J Hepatol, 2009, 51 (4) :810-820. [3]Bouchard MJ, Schneider RJ.The enigmatic X gene of hepa-titis B virus[J].J Virol, 2004, 78 (23) :12725-12734. [4]Chisari FV.Unscrambling hepatitis C virus-host interactions[J].Nature, 2005, 436 (7053) :930-932. [5]Feitelson MA, Reis HM, Lale Tufan N, et al.Putative rolesof hepatitis B x antigen in the pathogenesis of chronic liverdisease[J].Cancer Lett, 2009, 286 (1) :69-79. [6]Kordes C, Sawitza I, Müller-Marbach A, et al.CD133+he-patic stellate cells are progenitor cells[J].Biochem BiophysRes Commun, 2007, 352 (2) :410-417. [7]Roskams T.Different types of liver progenitor cells and theirniches[J].J Hepatol, 2006, 45 (1) :1-4. [8]Gaudio E, Carpino G, Cardinale V, et al.New insights intoliver stem cells[J].Dig Liver Dis, 2009, 41 (7) :455-462. [9]Caldwell S, Park SH.The epidemiology of hepatocellular canc-er:from the perspectives of public health problem to tumor biol-ogy[J].J Gastroenterol, 2009, 44 (Suppl XIX) :96-101. [10]Madhoun MF, Fazili J, Bright BC, et al.Hepatitis C preva-lence in patients with hepatocellular carcinoma without cir-rhosis[J].Am J Med Sci, 2010, 339 (2) :169-173. [11] Chen CJ, Yang HI, Su J, et al.Risk of hepatocel-lular car-cinoma across a biological gradient of serum hepatitis B virusDNA level[J].JAMA, 2006, 295 (1) :65-73. [12]Yang HI, Yeh SH, Chen PJ, et al.REVEAL-HBV Study Group.Associations between hepatitis B virus genotype and mutantsand the risk of hepatocellular carcinoma[J].J Natl Cancer Inst, 2008, 100 (16) :1134-1143. [13]Chan HL, Tse CH, Mo F, et al.High viral load and hepatitisB virus subgenotype Ce are associated with increased risk ofhepatocellular carcinoma[J].J Clin Oncol, 2008, 26 (2) :177-182. [14]Hung IFN, Poon RTP, Lai CL, et al.Recurrence of hepatitisB-related hepatocellular carcinoma is associated with highviral load at the time of resection[J].Am J Gastroenterol, 2008, 103 (7) :1663-1673. [15]Chen CJ, Yang HI, Iloeje UH, et al.Hepatitis B virus DNAlevels and outcomes in chronic hepatitis B[J].Hepatology, 2009, 49 (5 Suppl) :S72-84. [16]El-Serag HB.Epidemiology of viral hepatitis and hepatocel-lular carcinoma[J].Gastroenterology, 2012, 142 (6) :1264-1273. [17]Shi J, Zhu L, Liu S, et al.A meta-analysis of case-controlstudies on the combined effect of hepatitis B and C virus in-fections in causing hepatocellular carcinoma in China[J].BrJ Cancer, 2005, 92 (3) :607-612. [18]Wu CY, Chen YJ, Ho HJ, et al.Association between nucle-oside analogues and risk of hepatitis B virus-related hepato-cellular carcinoma recurrence following liver resection[J].JAMA, 2012, 308 (18) :1906-1913. [19]Lok ASF.Does antiviral therapy prevent recurrence of hepati-tis B virus-related hepatocellular carcinoma after curative liv-er resection[J].JAMA, 2012, 308 (18) :1922-1924. [20]Sun HC, Tang ZY, Wang L, et al.Postoperative interferon al-pha treatment postponed recurrence and improved overallsurvival in patients after curative resection of HBV-relatedhepatocellular carcinoma:a randomized clinical trial[J].JCancer Res Clin Oncol, 2006, 132 (7) :458-465. [21]Lo CM, Liu CL, Chan SC, et al.A randomized, controlledtrial of postoperative adjuvant interferon therapy after resec-tion of hepatocellular carcinoma[J].Ann Surg, 2007, 245 (6) :831-842. [22]Zhang CH, Xu GL, Jia WD, et al.Effects of interferon alphatreatment on recurrence and survival after complete resectionor ablation of hepatocellular carcinoma:A meta-analysis ofrandomized controlled trials[J].Int J Cancer, 2009, 124 (12) :2982-2988. [23]Breitenstein S, Dimitroulis D, Petrowsky H, et al.Systemat-ic review and meta-analysis of interferon after curativetreatment of hepatocellular carcinoma in patients with viralhepatitis[J].Br J Surg, 2009, 96 (9) :975-981. [24]Chen LT, Chen MF, Li LA, et al.Long-term results of arandomized, observation-controlled, phase III trial of adju-vant interferon Alfa-2b in hepatocellular carcinoma after cur-ative resection[J].Ann Surg, 2012, 255 (1) :8-17. [25]Tanimoto Y, Tashiro H, Aikata H, et al.Impact of pegylatedinterferon therapy on outcomes of patients with hepatitis Cvirus-related hepatocellular carcinoma after curative hepaticresection[J].Ann Surg Oncol, 2012, 19 (2) :418-425. [26]Hagihara H, Nouso K, Kobayashi Y, et al.Effect of pegylat-ed interferon therapy on intrahepatic recurrence after curativetreatment of hepatitis C virus-related hepatocellular carcino-ma[J].Int J Clin Oncol, 2011, 16 (3) :210-220. [27]Kawaoka T, Aikata H, Takaki S, et al.IL28B polymorphism mayguide pegylated interferon plus ribavirin therapy even after cura-tive treatment for hepatitis C virus-related hepatocellular carci-noma[J].J Viral Hepatitis, 2011, 18 (10) :e550-e560. [28]Everson GT, Trotter J, Forman L, et al.Treatment of advancedhepatitis C with a low accelerating dosage regimen of antiviraltherapy[J].Hepatology, 2005, 42 (2) :255-262. [29]Bzowej N, Nelson DR, Terrault NA, et al.PHOENIX:A ran-domized controlled trial of peginterferon alfa-2a plus ribavirinas a prophylactic treatment after liver transplantation for hep-atitis C virus[J].Liver Transpl, 2011, 17 (5) :528-538. [30]Omata M, Lesmana LA, Tateishi R, et al.Asian Pacific As-sociation for the study of the Liver consensus recommendut-ions on hepatocellular carcinoma[J].Hepatol Int, 2010, 4 (2) :439-474. [31] Asian-Pacific consensus statement on the management ofchronic hepatitis B:a 2012 update[J].Hepatol Int, 2012, 6 (3) :531-561.
本文二维码
计量
- 文章访问数: 4070
- HTML全文浏览量: 12
- PDF下载量: 1185
- 被引次数: 0